Dear Investigators,

The Experimental Therapeutics Clinical Trials Network (ETCTN), will employ a team science approach for drug development, while integrating research resources and programs across the NCI. Teams will work together to define the best path forward for the development of new drugs. This team science approach should allow NCI-sponsored investigators to perform high impact clinical trials enriched with molecular characterization of patients and sophisticated scientific research. The goal is to move toward the more precise selection of patients for participation on clinical studies and efficient and timely trial completion. Along the way we hope to enhance interaction and collaboration as well as improving the training of the next generation of drug developers.

The AMG 232 Project Team Member Application (PTMA) is a part of the new CTEP ETCTN process and will be studying AMG 232, a potent, selective, orally (PO) available, piperidinone small molecule inhibitor, that can inhibit the interaction between the tumor suppressor protein p53 and the human homolog of murine double minute 2 (Mdm2) (Rew and Sun, 2014; Sun et al., 2014). The PTMA replaces the former Mass Solicitation and is intended to enable CTEP to identify investigators who will be invited to participate in the AMG 232 Project Team. Clinical, translational, and basic scientists will convene to discuss the AMG 232 draft development plan and to modify it as needed. Dr. Naoko Takebe will lead the team along with one of the investigators chosen through the PTMA process. Reference materials regarding the Team Science approach are also included in this email, along with the current Project Team Member Application (PTMA) template (Version 5.0, July 31, 2015), which has been modified specifically for the AMG 232 Project Team Applications . Please use the Submission Form on the NRG website for your submission .

The last day to receive your submission for the AMG 232 PTMA is Tuesday, January 5, 2016 at 5 PM (ET). Please be aware of server problems or e-mail issues that may cause your submission to be delayed and do take appropriate measures to ensure your proposal arrives before the deadline.

When submitting your PTMA form, please use the following subject line " AMG 232 PTMA – Applicant’s Name" to assist PIO staff in categorizing your submission.

Please note the following:

  • All applicants must have an active CTEP Identity and Access Management (IAM) Account before the submission deadline. If you have not previously registered for a CTEP-IAM account, please go to go to and click the “Request New Account” link at the right. For questions about CTEP-IAM account creation, please contact the CTEP Registration Help Desk: .
  • Before submitting your PTMA form (Version 5.0, July 31, 2015; please use only this version), please check carefully for accuracy and completeness. Once you have submitted the PTMA form, please do not send a revision until after CTEP has completed its initial review and you have received an email with the assigned PTMA number. This will greatly reduce abstraction errors and confusion.
  • Should you wish to apply for multiple roles (e.g., as a Basic and Translational scientist), please submit one application and indicate each role for which you would like to be considered.
  • If you plan on submitting more than one PTMA form (i.e., you are submitting forms on behalf of multiple applicants), please send each PTMA form in a separate email.
  • Interested applicants should notify NRG Oncology Leadership and submit PTMA to the appropriate protocol development office.
    • Research Strategy Committee Chair [Mitchell Machtay (]
    • Disease Site Committee Chair and/or Non-Disease Site Scientific Committee Chair (DT and/or Translational Science)
    • Copy Protocol Development Office [Francy Fonzi (, Kia Neff (, Nancy Soto (]
  • Applicants, please submit the form to the NRG protocol development office by December 22nd. NRG Oncology will submit the application to CTEP by the deadline of January 5, 2016.
View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103